Viridian Therapeutics (LTS:0K1R) Other Current Liabilities: $14.17 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0K1R Viridian Therapeutics Inc LTS:0K1R
49 GF Score
Price $23.38
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Viridian Therapeutics Other Current Liabilities?

Viridian Therapeutics LTS:0K1R +2.01% 49 Other Current Liabilities is $14.17 Mil as of Jun. 2026. GuruFocus rates LTS:0K1R with a GF Score™ of 49/100 (Possible Value Trap). The stock has 5 warning signs investors should review.

Viridian Therapeutics's other current liabilities for the quarter that ended in Jun. 2026 was $14.17 Mil.

Viridian Therapeutics's quarterly other current liabilities declined from Dec. 2025 ($19.66 Mil) to Mar. 2026 ($8.36 Mil) but then increased from Mar. 2026 ($8.36 Mil) to Jun. 2026 ($14.17 Mil).

Viridian Therapeutics's annual other current liabilities increased from Dec. 2023 ($10.61 Mil) to Dec. 2024 ($10.64 Mil) and increased from Dec. 2024 ($10.64 Mil) to Dec. 2025 ($19.66 Mil).

Viridian Therapeutics Other Current Liabilities Related Terms

Viridian Therapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Viridian Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viridian Therapeutics Other Current Liabilities Chart

Viridian Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.75 4.87 10.61 10.64 19.66

Viridian Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.19 10.71 19.66 8.36 14.17
LTS:0K1R
49GF Score
Viridian Therapeutics Inc LTS:0K1R
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viridian Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $14.17 Mil mean?
Viridian Therapeutics (LTS:0K1R) has a Other Current Liabilities of $14.17 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Viridian Therapeutics.
Is Viridian Therapeutics' Other Current Liabilities too high?
Viridian Therapeutics' current Other Current Liabilities is $14.17 Mil. Overall, Viridian Therapeutics has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Viridian Therapeutics' Other Current Liabilities compare to BHVN and AGIO?
Viridian Therapeutics' Other Current Liabilities of $14.17 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Viridian Therapeutics. Viridian Therapeutics's current Other Current Liabilities is $14.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viridian Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Viridian Therapeutics (LTS:0K1R) is currently considered Possible Value Trap. The current Other Current Liabilities is $14.17 Mil. Viridian Therapeutics' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Viridian Therapeutics (LTS:0K1R), the current Other Current Liabilities is $14.17 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viridian Therapeutics Business Description

Other Exchanges VRDN:USA1S1:Germany
Address 221 Crescent Street, Suite 103A, Waltham, MA, USA, 02453
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
49GF Score

Get the complete analysis for LTS:0K1R

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.38
Price